China SXT Pharmaceuticals, Inc.

SXTC

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
SXTC
CIK0001723980
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address178 TAIDONG ROAD NORTH, TAIZHOU, F4, 225300
Website sxtchina.com
Phone8652386298290
CEOFeng Zhou
Employees90

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$1.74 million
Pre-Tax Income$-3.30 million
Net Income$-3.30 million
Net Income to Common$-3.30 million
EPS$-2.32
View All
Balance Sheet
Cash$18.10 million
Assets$21.66 million
Liabilities$6.22 million
Common Equity$15.44 million
Liabilities & Equity$21.66 million
View All
Cash Flow Statement
Calculations
NOPAT$-1.88 million
EBITDA$-2.60 million
Price to EarningsN/A
Price to BookN/A
ROE-22.50%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

BC-Most Active Stocks

td class="col-issue">Next Technology Holding Inc.

Article Link

China SXT Pharmaceuticals Full Year 2025 Earnings: US$2.32 loss per share (vs US$28.58 loss in FY 2024)

China SXT Pharmaceuticals ( NASDAQ:SXTC ) Full Year 2025 Results Key Financial Results Revenue: US$1.74m (down 9.7...

Article Link

US Market's Undiscovered Gems Featuring 3 Promising Stocks

As the United States market continues to experience robust economic growth and strong corporate earnings, major indices like the S&P 500 and Nasdaq Composite are reaching new heights, driven by optimism despite lingering tariff concerns. In this dynamic environment, identifying promising stocks requires a keen eye for companies that demonstrate resilience and potential for growth amid broader market trends.

Article Link

Undiscovered Gems in the US Market for July 2025

Over the last seven days, the United States market has remained flat, yet it has seen a significant 16% increase over the past year with expectations of earnings growing by 15% annually in the coming years. In this dynamic environment, identifying stocks that are not only resilient but also poised to capitalize on growth opportunities can be key to uncovering potential undiscovered gems.

Article Link

US Undiscovered Gems with Strong Potential July 2025

As the S&P 500 and Nasdaq Composite continue to reach new highs, fueled by strong corporate earnings and easing tariff concerns, investors are closely watching the Federal Reserve's upcoming meeting on interest rates. This environment of optimism and economic resilience presents a fertile ground for identifying promising opportunities among small-cap stocks. In this context, discovering stocks with solid fundamentals and growth potential can be particularly rewarding, as they may offer unique...

Article Link